Fluorescence In-Situ Hybridization Probe Market size is likely to depict significant growth from 2023 to 2032 due to a noticeable rise in incidences of chronic diseases, including genetic and cancer disorders. According to WHO estimates, genetic disorders and congenital abnormalities occur in nearly 2% to 5% of live births, accounting for up to 30% of pediatric hospital admissions, while leading to 50% of childhood deaths in industrialized countries.
Fluorescence in-situ hybridization (FISH) technique boasts wide applications in the diagnostics industry, including the identification of structural and numerical anomalies in chromosomes, therapeutic drug monitoring, characterization of marker chromosomes, and rare and genetic disease identification. It also has applications in clinical research, such as gene mapping and the characterization of somatic cell hybrids.
The fluorescence in-situ hybridization probe market growth is further propelled by the escalating R&D initiatives by prominent industry players focused on developing specific biomarkers and products. Besides, the growing cognizance of the advantages associated with early detection and treatment coupled with the increasing healthcare expenditure and development of novel probes may stimulate the FISH probe market progression over the next ten years.
Huge financial costs associated with fluorescence in-situ hybridization probes, market presence of other economical alternatives, and lack of skilled professionals and knowledge of the technology are some of the restricting factors hindering the market growth. Besides, the crashing healthcare infrastructure and declining economic growth as a result of the ongoing war between Ukraine and Russia will further impact fluorescence in-situ hybridization probe market dynamics.
Based on the type of technique, the Flow-FISH segment is anticipated to account for lucrative gains through 2032. The technique is suitable for the concomitant detection of protein and RNA. This enables the identification of cells expressing a gene and simultaneously converts it into protein. In addition, the extensive utilization of the given technique as a diagnostic test for telomere length measurement in humans will augment segment share in the foreseeable future.
FISH probes are largely used for lung cancer detection. Due to this, the lung cancer application segment of the fluorescence in-situ hybridization probe market is expected to grow at a decent pace between 2023 and 2032. This can be ascribed to the rising cases of lung cancer worldwide. As per Cancer.org, lung cancer is considered one of the leading causes of cancer deaths, accounting for 25% of all cancer deaths globally. FISH probes detect chromosomal alternations that underlie the progression and development of lung cancer and pinpoint targets of new anticancer drugs.
North America fluorescence in-situ hybridization probe market is slated to accumulate a sizeable market share by 2032, driven by the surging incidences of genetic disorders and cancer in developed economies. According to reliable estimates, genetic disorders are likely to affect the lives of nearly 500,000 children in Canada. FISH probes are estimated to offer high accuracy in the detection of chromosomal abnormalities leading to such disorders.
Leading players in the global fluorescence in-situ hybridization probe industry include Abnova Corporation, Abbott Laboratories, F. Hoffmann-La Roche AG, PerkinElmer, and Biosearch Technologies (LGC Biosearch Technologies), among others. Companies operating in this industry are taking up organic strategies like acquisitions & mergers, partnerships, and product launches to strengthen their position in the overall market.